Outlook Therapeutics, Inc. 8K

Outlook Therapeutics, Inc. agreed on a without‑cause separation and severance package for CFO Lawrence A. Kenyon, including equity vesting acceleration and potential enhanced change‑in‑control benefits, in connection with his transition out of all roles in September 2026.

Outlook Therapeutics, Inc. entered into a separation agreement with Lawrence A. Kenyon under which he will cease serving as Chief Financial Officer, Treasurer, Corporate Secretary, and from all other positions with the company and its subsidiaries effective September 1, 2026, will remain as a non‑executive employee through a transition period ending on or before September 30, 2026, and will resign from the Board of Directors by the planned separation date. In exchange for a general release of claims and compliance with post‑employment obligations, the company will provide severance benefits following his termination without cause, including a lump‑sum cash payment equal to 12 months of base salary plus $20,000, a 2026 target bonus, full acceleration of time‑based vesting on all outstanding equity awards as of the separation date, and up to 12 months of company‑paid COBRA premiums (or equivalent taxable payments if direct COBRA subsidies are impermissible). If a qualifying change in control occurs within two months after the separation date, enhanced change‑in‑control severance will apply instead of the standard package, consisting of a lump‑sum payment equal to 18 months of base salary plus $20,000, an enhanced bonus equal to 150% of his 2026 target bonus (18/12), and up to 18 months of COBRA coverage or equivalent cash payments, with such change‑in‑control benefits offset by any severance already paid. The agreement also addresses return of company property, continued confidentiality and invention assignment obligations, cooperation with legal matters, mutual non‑disparagement, and standard Section 409A and release‑of‑claims provisions, and is governed by Illinois law.

Filing Facts

CIK

1649989

Ticker

-

Form

8K

Source Type

sec

Accession

0001104659-26-102446

Alert Tier

7